
|Videos|December 16, 2017
Sotatercept in Patients With MPN-Associated Myelofibrosis and Anemia
Author(s)Srdan Verstovsek, MD
Srdan Verstovsek, MD, of MD Anderson Cancer Center, discusses a study of sotatercept (ACE-011) alone and in combination with ruxolitinib in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5









































